TIVC icon

Tivic Health Systems

3.50 USD
-0.18
4.89%
At close Apr 17, 4:00 PM EDT
1 day
-4.89%
5 days
-20.63%
1 month
6.06%
3 months
-29.86%
6 months
-26.47%
Year to date
-39.97%
1 year
-81.62%
5 years
-99.96%
10 years
-99.96%
 

About: Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.

Employees: 7

0
Funds holding %
of 7,407 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

30% more capital invested

Capital invested by funds: $69.8K [Q3] → $90.7K (+$20.9K) [Q4]

0% more funds holding

Funds holding: 10 [Q3] → 10 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

1.7% less ownership

Funds ownership: 4.53% [Q3] → 2.83% (-1.7%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for TIVC.

Financial journalist opinion

Based on 4 articles about TIVC published over the past 30 days

Neutral
Business Wire
3 days ago
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™. Neutropenia is a condition characterized b.
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia
Neutral
Business Wire
1 week ago
Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health's common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “TIVC.” About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics com.
Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
Neutral
Seeking Alpha
4 weeks ago
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript
Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q4 2024 Results Conference Call March 21, 2025 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Lisa Wolf - Interim Chief Financial Officer Operator Welcome to Tivic Health Systems Year-End 2024 Financial Results and Operational Update Conference Call. This call has been prerecorded and the questions you have submitted in advance will be answered following prepared remarks.
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript
Neutral
Business Wire
4 weeks ago
Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. “The important strategic events of the past several months have been nothing short of transformative,” stated Tivic Health Chief Executive Officer, Jennifer Ernst. “We have successfully reshaped the.
Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth
Neutral
Business Wire
1 month ago
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID.
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast
Neutral
Business Wire
1 month ago
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to c.
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System
Neutral
Business Wire
1 month ago
Tivic Health Systems, Inc. Announces Reverse Stock Split
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic Health” or the “Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (“Nasdaq”), and is part of the.
Tivic Health Systems, Inc. Announces Reverse Stock Split
Neutral
Business Wire
1 month ago
Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with the U.S. Patent Office. Patent No. 63,492,402, entitled “Method and Apparatus for Electrical Stimulation of the Vagus Nerve,” expands the claims and protection around the technology in advance of potential U.S. Food &amp.
Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve
Neutral
Business Wire
1 month ago
Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to deve.
Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team
Neutral
Business Wire
2 months ago
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement estab.
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma
Charts implemented using Lightweight Charts™